Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YANIS BOUMBER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1780870428
CMS profile
35509
Location
MARION, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$320.66

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $320.66 11

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YANIS BOUMBER

NPI 1780870428 · CMS profile ID 35509

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MARION, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780870428?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YANIS BOUMBER, NPI 1780870428, CMS profile ID 35509. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780870428?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). YANIS BOUMBER, NPI 1780870428, CMS profile ID 35509. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780870428?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
YANIS BOUMBER, NPI 1780870428, CMS profile ID 35509, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780870428?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $320.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $34.1711/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244520032 CMS
Merck Sharp & Dohme LLC $28.3210/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238331097 CMS
Genentech, Inc. $34.9609/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211609224 CMS
Janssen Scientific Affairs, LLC $20.7308/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174187657 CMS
AstraZeneca Pharmaceuticals LP $16.8408/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207060156 CMS
Amgen Inc. $63.8806/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228421325 CMS
Amgen Inc. $31.9406/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228421327 CMS
Novocure Inc. $20.7906/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251152354 CMS
Pharmacosmos Therapeutics Inc. $27.0705/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250725844 CMS
Janssen Biotech, Inc. $24.2904/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174357190 CMS
Novocure Inc. $17.6702/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251152352 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,228.57 3
PY2020 $555.00 1
PY2021 $28,547.19 33
PY2022 $39,638.92 55
PY2023 $28,800.48 41
PY2024 $32.46 2
PY2025 $320.66 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,163,336.81 68
PY2024 Principal investigator $202,666.13 3
PY2023 Principal investigator $71,339.59 2
PY2022 Principal investigator $5,230.30 2
PY2021 Principal investigator $34,755.91 1
PY2020 Principal investigator $5,463.26 2
PY2019 Principal investigator $35,100.03 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,073.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796367
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,640.00 12/05/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796363
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 12/05/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796365
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577780
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $319.42 11/10/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796361
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577778
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $327,443.41 10/31/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997044
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $151.00 10/30/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796359
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42,483.00 10/09/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796351
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577776
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,295.00 10/01/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796357
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $306,978.20 09/30/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997046
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $205.10 09/24/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997022
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $104.94 09/24/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997024
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $139.86 09/24/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997026
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10.64 09/24/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997028
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6.00 09/24/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997030
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,640.00 09/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796355
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,963.00 09/18/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796349
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $604.00 09/03/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796353
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 09/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577774
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $293.00 08/26/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997036
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $34.98 08/26/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997038
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $139.86 08/26/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997040
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.40 08/26/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997042
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $37,865.00 08/20/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796343
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $159.71 08/20/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796345
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $151.00 08/04/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796347
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 08/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577768
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $39,676.00 08/01/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796341
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,600.00 07/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796335
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $151.00 07/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796337
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 07/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796339
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $132,151.90 07/14/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796333
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 07/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577766
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $310.26 06/05/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796331
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 06/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577760
Principal investigator 1 Boehringer Ingelheim Espana S.A. $20.98 06/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577762
Principal investigator 1 Boehringer Ingelheim Espana S.A. $107.76 06/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577764
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $57,808.00 05/29/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796329
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $302.00 05/28/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796325
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,984.00 05/28/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796327
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $146.50 05/27/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997016
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $93.28 05/27/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997018
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $99.90 05/27/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997020
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $15.96 05/27/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997032
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4.80 05/27/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997034
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577758
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $498.10 04/23/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997006
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $23.32 04/23/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997008
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $139.86 04/23/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997010
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10.64 04/23/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997012
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.40 04/23/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997014
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 04/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796311
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $155.13 04/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796313
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,116.00 04/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796315
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,699.00 04/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796317
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 04/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796319
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $39,762.00 04/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796321
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,520.00 04/23/2025 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220796323
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 04/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577754
Principal investigator 1 Boehringer Ingelheim Espana S.A. $71.84 04/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577756
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 03/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577752
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $87.90 02/25/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997000
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $81.62 02/25/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997002
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $59.94 02/25/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997004
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 02/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577772
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 01/01/2025 Non-covered Recipient Entity
Kirklin Clinic Of UAB Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577770